Euro-Celtique S.A.
41 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 8 name spellings.
2
Ending by 2030
Feb 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 18, 2027.
Recent changes
- 2 terms have ended since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,383,842 | Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol In force · From the USPTO record | In force | From the USPTO record | |
| US 9,814,679 | Tamper resistant dosage form comprising a matrix and melt-extruded particulates comprising a drug In force · From the USPTO record | In force | From the USPTO record | |
| US 9,901,540 | Combination of active loaded granules with additional actives In force · From the USPTO record | In force | From the USPTO record | |
| US 9,993,433 | Manufacturing of active-free granules and tablets comprising the same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,764,102 | Dispenser cap arrangement In force · From the USPTO record | In force | From the USPTO record | |
| US 10,688,258 | Dispenser cap arrangement In force · From the USPTO record | In force | From the USPTO record | |
| US 9,805,300 | Counter In force · From the USPTO record | In force | From the USPTO record | |
| US 9,750,902 | Dispenser In force · From the USPTO record | In force | From the USPTO record | |
| US 10,071,089 | Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation In force · From the USPTO record | In force | From the USPTO record | |
| US 10,258,616 | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 10: 41 patents in force now held by others · 79 lapsed for an unpaid fee · 303 ended at full term · 4 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
36 abandoned · 39 no status recorded